within Pharmacolibrary.Drugs.ATC.A;

model A10BJ06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.833333333333333e-07,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0125,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0222,
    k12             = 0.048,
    k21             = 0.048
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BJ06</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy subjects and patients with type 2 diabetes (predominantly adults), after subcutaneous administration.</p><h4>References</h4><ol><li><p>Yang, XD, &amp; Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. <i>Drug design, development and therapy</i> 18 2555–2570. DOI:<a href=\"https://doi.org/10.2147/DDDT.S470826\">10.2147/DDDT.S470826</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38952487/\">https://pubmed.ncbi.nlm.nih.gov/38952487</a></p></li><li><p>Shi, A, et al., &amp; Haugaard, SP (2021). Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <i>Advances in therapy</i> 38(1) 550–561. DOI:<a href=\"https://doi.org/10.1007/s12325-020-01548-y\">10.1007/s12325-020-01548-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33159658/\">https://pubmed.ncbi.nlm.nih.gov/33159658</a></p></li><li><p>Hall, S, et al., &amp; Clements, JN (2018). Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical pharmacokinetics</i> 57(12) 1529–1538. DOI:<a href=\"https://doi.org/10.1007/s40262-018-0668-z\">10.1007/s40262-018-0668-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29915923/\">https://pubmed.ncbi.nlm.nih.gov/29915923</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BJ06;
